[go: up one dir, main page]

WO2006121098A1 - Composition de film de capsules molles - Google Patents

Composition de film de capsules molles Download PDF

Info

Publication number
WO2006121098A1
WO2006121098A1 PCT/JP2006/309448 JP2006309448W WO2006121098A1 WO 2006121098 A1 WO2006121098 A1 WO 2006121098A1 JP 2006309448 W JP2006309448 W JP 2006309448W WO 2006121098 A1 WO2006121098 A1 WO 2006121098A1
Authority
WO
WIPO (PCT)
Prior art keywords
soft capsule
film composition
present
seamless
capsule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2006/309448
Other languages
English (en)
Japanese (ja)
Inventor
Akira Oomori
Hideyuki Terasawa
Yuu Oogo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mochida Pharmaceutical Co Ltd
Fuji Capsule Co Ltd
Original Assignee
Mochida Pharmaceutical Co Ltd
Fuji Capsule Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharmaceutical Co Ltd, Fuji Capsule Co Ltd filed Critical Mochida Pharmaceutical Co Ltd
Publication of WO2006121098A1 publication Critical patent/WO2006121098A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Definitions

  • the present invention relates to a non-animal soft capsule film composition used for foods, cosmetics, quasi drugs, pharmaceuticals and the like.
  • gelatin made mainly from bones and skins of swine pigs has been used in many cases.
  • animal-derived materials such as gelatin have seen the occurrence of mad cow disease (BSE), etc., and their problems have been pointed out from the viewpoint of safety, stable supply, etc., and there has been a shift to non-animal materials.
  • BSE mad cow disease
  • non-animal soft capsule films As materials for non-animal soft capsule films, agar, starch, modified starch, pullulan, other water-soluble polymers, and combinations thereof have been studied. From the viewpoint of practicality that comprehensively judges strength, disintegration, etc., compared to the above, it is still not enough as a substitute. More specifically, the known soft capsule film has a problem that when it is placed in an environment having a temperature of 25 ° C. and a relative humidity of 50% or more, the film strength rapidly decreases due to moisture absorption. ing.
  • a soft capsule film composition for seamless capsules using dextrin as a base and carrageenan as a gelling agent mixed with the base is known (for example, a patent Reference 1).
  • non-gelatin capsule film composition comprising a starch degradation product having a DE of less than DE10 and an average molecular weight of 30,000 or less as a base and a gelling agent (for example, see Patent Document 2). ).
  • a soft capsule film made of a water-soluble polymer, a dextrin of DE12 or less, trehalose, and the like is known (for example, see Patent Document 3).
  • Soft capsules based on polyvinyl alcohol are also known (for example, patents) (Ref. 4).
  • non-animal water-soluble polymers polybulal alcohol and Z or polybulur pyrrolidone, and a gelling agent are essential components, and a soft combination of these.
  • a gelling agent is essential components, and a soft combination of these.
  • Patent Document 1 Japanese Patent Application Laid-Open No. 2004-250369
  • Patent document 2 International publication 03Z43609 pamphlet
  • Patent Document 3 Japanese Unexamined Patent Application Publication No. 2004-167084
  • Patent Document 4 Japanese Patent Publication No. 45-1277
  • the problem to be solved by the present invention is that the soft capsule film composition itself has excellent production characteristics (easiness of operation, etc.), and the resulting soft capsule has sufficient physical strength (initial rigidity and Foods that have high bursting strength, etc., excellent stability against humidity and heat, good disintegration, that is, excellent liquid content release, excellent discharge from containers and bags, and little adhesion between capsules It is an object of the present invention to provide a non-animal soft capsule coating composition that can be used as a safe soft capsule for pharmaceuticals, especially a seamless capsule.
  • the non-animal soft capsule coating composition of the present invention itself has excellent production characteristics.
  • the obtained soft capsules have high physical strength, excellent stability against humidity and heat, excellent disintegration, that is, excellent release of liquid contents, excellent discharge from containers and bags, Fewer features such as being safe for food and pharmaceuticals with less adhesion Soft capsules with at least one, especially seamless capsules.
  • non-animal water-soluble polymer is used as the base of the soft capsule obtained from the soft capsule film composition.
  • the non-animal water-soluble polymer used in the present invention is not particularly limited as long as it is applicable as a food or a pharmaceutical product. Examples thereof include starch, modified starch, agar, pullulan, hydroxypropylmethylcellulose, sodium alginate and the like. . These non-animal water-soluble polymers may be used alone or in combination. More specifically, dextrin is preferred than modified starch. Several types of dextrin are known depending on the production method and glucose equivalence value (hereinafter abbreviated as DE), etc., but they are not particularly limited as long as they are applicable as foods and pharmaceuticals.
  • DE glucose equivalence value
  • the total amount of the non-animal water-soluble polymer is 80% by mass or less, preferably 60% by mass or less, based on the total solid component mass in the soft capsule film composition.
  • polybulal alcohol hereinafter sometimes abbreviated as PVA
  • Z or polybulur pyrrolidone hereinafter sometimes abbreviated as PVP
  • PVA polybulal alcohol
  • PVP polybulur pyrrolidone
  • the degree of polymerization of PVA is 300 to 4000, and the degree of saponification is preferably 78 mol% or more.
  • the degree of polymerization is preferably 400 to 800, and the degree of saponification is preferably 78 to 90 mol%.
  • the degree of polymerization of PVP is preferably a K value of 20 to 90. A K value of 25 to 40 is particularly preferred.
  • PVA and PVP are used alone or in combination.
  • the preferred ratio (mass) of both is PVPO.1 to 10 with respect to PVA1
  • the more preferred ratio is PVPO.3 to 3 with respect to PVA1
  • the total amount of PVA and Z or PVP is 90% by mass or less, preferably 10 to 70% by mass, more preferably 15% by mass with respect to the total solid content in the soft capsule film composition. ⁇ 50% by weight.
  • the gelling agent used in the present invention is not particularly limited as long as it can be applied as a food or a medicine.
  • the gelling agent used in the present invention is not particularly limited as long as it can be applied as a food or a medicine.
  • carrageenan sodium alginate, guar gum, locust bean gum, tara gum, xanthan gum, cellulose derivative, carboxyvinyl polymer, etc. Is mentioned.
  • These gelling agents may be used alone or in combination of two or more.
  • force laginan is preferable.
  • carrageenan is known as ⁇ -strength laginan, ⁇ -strength laginan, t- strength laginan, ⁇ -strength laginan, etc.
  • the present invention is not particularly limited and can be used in the present invention.
  • GENUGEL ⁇ -carrageenan, CP Kelco
  • NE WGELIN K- and t-carrageenan, Chuo-Kaisei
  • carrageenin ⁇ 1, and t 'F' Eye Co., Ltd.
  • GENUVISCO I Isshiki Laginan, CP Kelco's
  • Gerrich T Isshiki Laginain, Saneigen F'F 'Co., Ltd.
  • ⁇ -carrageenan, t-strength laginan, and combinations thereof are preferable.
  • the preferred ratio (mass) of the combination of both ⁇ -powerful lagininan and t- strength laggynan is ⁇ -powerful laginan 1 to t- powerful laginan 0.1.
  • Forced laggy nan It is particularly preferable to use 1 ruggedan at 1 to 3: 1.
  • the amount of gelling agent The total amount is 40% by mass or less, preferably 5 to 20% by mass, based on the total solid mass in the soft capsule film composition.
  • copolyvidone may be used! /.
  • Copolyvidone is a copolymer of butyl acetate and 1-bul 1-pyrrolidone. Commercially available products can be used, and examples thereof include Plasdon S-630 (trade name; manufactured by IPS Japan Co., Ltd.).
  • the total amount of copolyvidone is 20% by mass or less, preferably 0.1 to 10% by mass, based on the total solid mass in the soft capsule film composition.
  • a gelling aid may be used.
  • Specific examples include salty potassium and salty calcium. These may be used alone or in combination. It is preferred to use potassium salt alone.
  • the blending amount of the gelation aid is 20% by mass or less, preferably 0.5 to 10% by mass, based on the total solid content in the soft capsule film composition.
  • a plasticizer may be used.
  • Specific examples include concentrated glycerin, saccharides (for example, trenosose, D-sonolebithonole, sucrose, mantonone, erythritole, maltitol, etc.). These may be used alone or in combination. It is preferable to use concentrated glycerin and saccharides in combination.
  • As the saccharide trehalose or D-sorbitol is preferable.
  • the total amount of the plasticizer is 55% by mass or less, preferably 10 to 35% by mass, based on the total solid mass in the soft capsule film composition.
  • components that can be usually blended in a soft capsule film composition such as a flavoring agent (for example, xylitol, etc.), a flavoring agent (for example, orange oil, heart force oil, etc.) ), Coloring agents, preservatives (eg sodium citrate, methyl noraoxybenzoate, propyl paraoxybenzoate, etc.), antioxidants (eg tocopherol, tocopherol acetate, propyl gallate, ascorbic acid stearate, Glycine, etc.), a pH adjuster (eg, sodium hydroxide, etc.) and the like can be appropriately blended as necessary.
  • a flavoring agent for example, xylitol, etc.
  • a flavoring agent for example, orange oil, heart force oil, etc.
  • Coloring agents eg sodium citrate, methyl noraoxybenzoate, propyl paraoxybenzoate, etc.
  • antioxidants eg tocopherol, tocopherol acetate, propyl gallate, ascor
  • the balance of the soft capsule film composition of the present invention is purified water.
  • the ratio (mass) of both is PVPO. 1 to LO
  • a gelling agent of 40% by mass or less is an essential component.
  • the soft capsule coating composition include 20% by mass or less of copolyvidone, 20% by mass or less of the gelling aid, and 55% by mass or less of the plasticizer as optional components, and preferably the soft capsule coating composition.
  • the type, size, shape, color, etc. of the soft capsule formed by filling the contents of the soft capsule film composition of the present invention there are no particular limitations on the type, size, shape, color, etc. of the soft capsule formed by filling the contents of the soft capsule film composition of the present invention.
  • As the kind of soft capsule seamless capsule is preferable.
  • the size and shape is usually a spherical shape with a diameter of 0.1-: L lmm, and a spherical shape with a diameter of 0.5 to 6 mm is preferred, and a spherical shape with a diameter of 3 to 5 mm is particularly preferred. Yes.
  • the contents of the soft capsule obtained from the soft capsule film composition of the present invention are not particularly limited, but pharmaceuticals and foods are preferred.
  • Specific examples of the contents include oils, that is, oils that are liquid at normal temperature, such as vegetable oils, fish oils, medium chain fatty acid triglycerides (MCT), polyunsaturated fatty acids, and the like.
  • oils that is, oils that are liquid at normal temperature, such as vegetable oils, fish oils, medium chain fatty acid triglycerides (MCT), polyunsaturated fatty acids, and the like.
  • MCT medium chain fatty acid triglycerides
  • Polyunsaturated fatty acids are preferred ⁇ -3 polyunsaturated fatty acids are particularly preferred.
  • ⁇ -3 polyunsaturated fatty acid power Sicosapentate acid, docosahexaenoic acid, ⁇ -linolenic acid power is at least one or a derivative thereof, and most preferably icosapentate acid ethyl ( Hereinafter, it may be abbreviated as EPA-E).
  • EPA-E icosapentate acid ethyl
  • a mixture of icosapentate ethyl and docosahexaenoate is also exemplified as a preferred content.
  • the content is refined fish oil and one or more selected from monoglycerides, diglycerides and triglycerides of polyunsaturated fatty acids.
  • medicinal ingredients such as the above-mentioned oil, for example, examples of preferred contents are those obtained by dissolving antihyperlipidemic drugs, antihypertensive drugs, antidiabetic drugs, antiobesity drugs, and the like.
  • a punching method (stubbing method) and a dropping method (dripping method), both of which are applicable to the present invention.
  • a liner-type or shearer-type rotary die method that is a kind of a stamping method and a submerged curing method that is a kind of a dropping method are used.
  • the liquid content of the discharge capsule inside the concentric double-structure nozzle, the capsule liquid composition of the outer discharge cartridge, or the coating film composition at a constant speed in the oil liquid or It is discharged into the gas, and the discharged liquid is cut at regular intervals by some physical force such as vibration, impact, flow rate difference between capsule liquid and oil liquid or gas, and the oil film or gas and force
  • a method of making spherical seamless capsules by interfacial or surface tension As a method for producing a soft capsule obtained from the soft capsule film composition of the present invention, a submerged curing method in which a dropping method is preferred is further preferred.
  • the soft capsule obtained by filling the soft capsule film composition of the present invention with the contents, the soft capsule having a diameter of about 4 mm and containing about 20 mg of EPA-E.
  • the initial stiffness value load necessary to deform the soft capsule by lmm
  • the initial stiffness value Soft capsules that maintain at least 3 NZmm, more preferably 5 NZmm, for at least 7 days.
  • a soft capsule formed by filling the contents of the soft capsule film composition of the present invention, which contains dextrin, polybulal alcohol and Z or polybulurpyrrolidone, and strength ruginan as essential components.
  • the soft capsule film composition of the present invention contains dextrin, polybulal alcohol and Z or polybulurpyrrolidone, and strength ruginan as essential components.
  • an initial stiffness value is measured using a hardness analyzer.
  • there is a soft capsule whose initial stiffness value is maintained at 3 NZmm or more, more preferably 5 NZmm or more for at least 7 days.
  • a soft capsule formed by filling the contents of the soft capsule film composition of the present invention about 20 mg of EPA-E containing about 4 mm in diameter is used.
  • EPA-E load required to burst (or break) the soft capsule
  • the soft capsule formed by filling the contents of the soft capsule film composition of the present invention which contains dextrin, polybulal alcohol and Z or polybulurpyrrolidone, and strength ruginan as essential components.
  • a hardness analyzer is used. When measuring burst strength values (loads required to rupture (or break) soft capsules), mention is made of soft capsules whose burst strength value is maintained at 15 N or more, more preferably 25 N or more for at least 7 days. It is done.
  • the physical strength can be expressed by initial stiffness, burst strength, etc., which satisfies both initial stiffness (3NZmm or more) and burst strength (15N or more) when left in the above environment. It can be regarded as having sufficient physical strength.
  • a coating solution ball was produced by the following method and used in the test described below. That is, the coating liquid heated to 75-80 ° C was dropped into a medium chain fatty acid triglyceride (hereinafter abbreviated as MCT) cooled to about 5 ° C to prepare a spherical coating liquid gel. A film obtained by drying the prepared film liquid gel was used as a film liquid ball.
  • MCT medium chain fatty acid triglyceride
  • Example 2 Each component shown in Table 2 was mixed to prepare a soft capsule coating solution for producing the soft capsule coating composition of the present invention. Using this coating solution, a coating solution ball was produced by the method of Example 1 and used in the test described below.
  • Each component shown in Table 3 is mixed to prepare a soft capsule film composition of the present invention.
  • a capsule film solution was prepared.
  • a coating solution ball was produced by the method of Example 1 and used in the test described below.
  • Example 1 Each component shown in Table 1 of Example 1 was mixed to prepare a soft capsule coating solution for producing the soft capsule coating composition of the present invention.
  • This film preparation solution is heated to 75 to 85 ° C., and the soft capsule film composition of the present invention having a diameter of about 4 mm and containing about 20 mg of EPA-E is obtained by a seamless capsule filling machine.
  • Seamless capsules were prepared. The seamless capsules were dried using an aeration rotary dryer, and then used in the tests described below.
  • Each component shown in Table 4 was mixed to prepare a soft capsule coating solution for producing the soft capsule coating composition of the present invention.
  • a seamless capsule made of the soft capsule coating composition of the present invention having a diameter of about 4 mm and containing about 20 mg of EPA-E was produced.
  • Each component shown in Table 5 was mixed to prepare a soft capsule coating solution for producing the soft capsule coating composition of the present invention.
  • a seamless capsule made of the soft capsule coating composition of the present invention having a diameter of about 4 mm and containing about 20 mg of EPA-E was produced.
  • Each component shown in Table 6 was mixed to prepare a soft capsule coating solution for producing the soft capsule coating composition of the present invention.
  • seamless capsules comprising the soft capsule coating composition of the present invention having a diameter of about 4 mm containing about 20 mg of EPA-E were prepared. Produced.
  • Each component shown in Table 7 was mixed to prepare a soft capsule coating solution for producing the soft capsule coating composition of the present invention.
  • a seamless capsule made of the soft capsule coating composition of the present invention having a diameter of about 4 mm and containing about 20 mg of EPA-E was produced.
  • Example 9 Each component shown in Table 8 was mixed to prepare a soft capsule coating solution for producing the soft capsule coating composition of the present invention.
  • Each component shown in Table 9 was mixed to prepare a soft capsule coating solution for producing the soft capsule coating composition of the present invention.
  • a seamless capsule made of the soft capsule coating composition of the present invention having a diameter of about 4 mm and containing about 20 mg of EPA-E was produced.
  • Each component shown in Table 10 was mixed to prepare a soft capsule coating solution for producing the soft capsule coating composition of the present invention.
  • seamless capsules comprising the soft capsule coating composition of the present invention having a diameter of about 4 mm and containing about 20 mg of EPA-E were prepared.
  • Each component shown in Table 11 is mixed to prepare the soft capsule film composition of the present invention.
  • a soft capsule film solution was prepared.
  • seamless capsules comprising the soft capsule coating composition of the present invention having a diameter of about 4 mm and containing about 20 mg of EPA-E were prepared.
  • Example 12 Each component shown in Table 12 was mixed to prepare a soft capsule film solution for producing a soft capsule film composition of a comparative example. Using this coating solution, a coating solution ball was produced by the method of Example 1 and used in the tests described below.
  • the glass vials containing the coating liquid balls obtained in Examples 1 to 3 and Comparative Example 1 were left in a 25 ° C.-60% RH environment without a cap, and 1 day and 7 days after the start of the test,
  • the initial stiffness of each coating solution ball was measured using a hardness analyzer (texture analyzer, TA-XT-PLUS, manufactured by Stable Micro Systems Ltd.).
  • the initial stiffness value refers to the load (NZmm) required to deform the skin film ball by lmm.
  • Table 14 shows the initial stiffness values of each coating liquid ball.
  • the coating liquid balls made of the soft capsule composition according to the present invention of Examples 1 to 3 are 25 ° in an open condition as compared with the coating liquid balls having the soft capsule coating composition force of Comparative Example 1.
  • C Example-Excellent initial stiffness when left in a 60% RH environment.
  • the soft capsule coating composition containing both PVA and PVP of Examples 1 and 3 Showed a better initial stiffness value.
  • the glass vials containing 40 coating liquid balls obtained in Examples 1 to 3 and Comparative Example 1 were left in a 25 ° C-60% RH environment without caps, and the test was started 1 day and 7 days later. Adhesion was measured. That is, the glass vial left under the above conditions was inverted and the number of falling coating liquid balls was measured. When all the film liquid balls did not fall, the vial was dropped from the desk surface at a height of lcm and 3cm, and the number of film liquid balls dropped by this treatment was counted. Table 15 shows the results of the adhesion test for each coating liquid ball. The numerical value is the number of coating liquid balls dropped from the left side upside down from the left. Z surface lcm force The number of coating liquid balls dropped by dropping the vial. Z desk surface 3cm force The film falling by dropping the vial. It means the number of liquid balls, and “one” means that the test has not been conducted under the above conditions as a result of the drop of all coating liquid balls.
  • the coating liquid balls made of the soft capsule composition according to the present invention in Examples 1 to 3 were in an open condition compared to the coating liquid balls also having the soft capsule coating composition force of Comparative Example 1. Adhesion was suppressed when left in an environment of 25 ° C-60% RH. In particular, in the case of the coating liquid ball having the soft capsule coating composition strength of the present invention, the adhesion was suppressed even after 7 days from the start of the test, and excellent characteristics under the conditions of this test were confirmed.
  • the glass vial containing the seamless capsules obtained in Examples 4 to 7 and Comparative Example 2 was left in a 25 ° C-50% RH environment without a cap, and 1 day and 7 days after the start of the test, Hardness analyzer (texture analyzer, TA—XT—PLUS, Stable Micro Sys terns Ltd.) was used to measure the initial stiffness and burst strength of each seamless capsule.
  • the initial stiffness value means the load (NZ mm) required to deform the seamless capsule by lmm
  • the burst strength value means the load (N) required to rupture (or break) the seamless capsule.
  • Table 16 shows the initial stiffness value and burst strength value of each seamless capsule.
  • the seamless capsules comprising the soft capsule coating compositions of the present invention of Examples 4 to 7 have an initial stiffness of 3N when left in an open condition at 25 ° C-50% RH. It had a sufficient physical strength with a Zmm or more and a burst strength of 15N or more.
  • the seamless capsules made of the soft capsule film composition containing both PVA and PVP in Examples 4 and 7 exhibited superior initial stiffness values and burst strength values.
  • the seamless capsule having the soft capsule film composition strength of Comparative Example 2 had an initial rigidity of 3 NZmm or less under the environment, and the physical strength was inferior.
  • the examples of the present invention that is, the non-animal water-soluble polymer, polyvinyl alcohol and z or polybylpyrrolidone, and the gelling agent are essential components.
  • the coating liquid balls or seamless capsules obtained from the soft capsule coating composition have no practical problems in all of the initial rigidity, burst strength, adhesion and disintegration tests, but the seamless capsule of the comparative example In addition, the coating liquid balls obtained results that seemed unsuitable for practical use.
  • the seamless capsules made of the soft capsule film composition of the present invention of Examples 8 to 12 have an initial stiffness of 3 NZmm or more when left in an open condition at 25 ° C-50% RH. Moreover, the burst strength was 15N or more, and it had sufficient physical strength. (Test Example 7) Adhesion
  • the seamless capsules made of the soft capsule film composition of the present invention of Examples 8 to 12 have suppressed adhesion when left in an open condition at 25 ° C-50% RH. It was.
  • the examples of the present invention that is, a soft ingredient containing non-animal water-soluble polymer, polyvinyl alcohol and Z or polybylpyrrolidone, and gelling agent as essential components.
  • the seamless capsule obtained from the capsule film composition does not cause any practical problems in all of the initial rigidity, burst strength, adhesion and disintegration test.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition de film de capsules molles excellente en termes de propriété de fabrication (telle qu’une manipulation aisée) et adaptée à une capsule molle d’origine non animale, en particulier une capsule sans raccord pouvant être utilisée sans risque comme produit alimentaire ou pharmaceutique, dans laquelle une capsule molle obtenue présente une force physique suffisante (comme la rigidité initiale et la résistance à l’éclatement) et présente d’excellentes caractéristiques de stabilité contre l’humidité et la chaleur, de désintégrabilité et de libération depuis un conteneur ou un sac ; lesdites capsules étant moins susceptibles d’adhérer les unes avec les autres. La composition de film de capsules molles contient un polymère hydrosoluble d’origine non animale, d’alcool polyvinylique et/ou de polyvinylpyrrolidone ainsi qu’un gélifiant en tant que composants essentiels.
PCT/JP2006/309448 2005-05-11 2006-05-11 Composition de film de capsules molles Ceased WO2006121098A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005138512 2005-05-11
JP2005-138512 2005-05-11

Publications (1)

Publication Number Publication Date
WO2006121098A1 true WO2006121098A1 (fr) 2006-11-16

Family

ID=37396606

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/309448 Ceased WO2006121098A1 (fr) 2005-05-11 2006-05-11 Composition de film de capsules molles

Country Status (1)

Country Link
WO (1) WO2006121098A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008117682A1 (fr) * 2007-03-27 2008-10-02 Sankyo Co., Ltd. Enveloppe de capsule molle, ne provenant pas d'un animal, et capsule molle pourvue de celle-ci
JP2011057746A (ja) * 2009-09-07 2011-03-24 Dai Ichi Kogyo Seiyaku Co Ltd ゲル状組成物
JP4822299B2 (ja) * 2009-06-19 2011-11-24 富士カプセル株式会社 ソフトカプセル及びその製造方法
JP4875769B2 (ja) * 2008-09-26 2012-02-15 株式会社三協 ソフトカプセルの製造方法並びにその製造装置
JP2013537902A (ja) * 2011-04-20 2013-10-07 サフン カプセル カンパニー， リミテッド 崩解度及び被膜硬度を改善した非動物性軟質カプセル被膜組成物
CN106243408A (zh) * 2016-08-26 2016-12-21 湖南尔康制药股份有限公司 一种改善机械性能的淀粉胶囊
WO2018225770A1 (fr) * 2017-06-09 2018-12-13 富士カプセル株式会社 Composition pour film de capsule sans soudure, et capsule sans soudure
CN109364039A (zh) * 2018-09-21 2019-02-22 浙江中同科技有限公司 一种淀粉空心胶囊及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000355534A (ja) * 1999-03-24 2000-12-26 Rheox Inc 薬剤、塗料ボールおよび他の調合物に使用することのできる、ゼラチンを含まない可撓性のあるカプセル材
JP2001170137A (ja) * 1999-12-16 2001-06-26 Shionogi Qualicaps Kk 硬質カプセル及びその製造方法
JP2002212063A (ja) * 2000-11-17 2002-07-31 Takeda Chem Ind Ltd コポリビドン含有製剤
JP2004250369A (ja) * 2003-02-19 2004-09-09 Fuji Capsule Kk 軟カプセル剤皮膜組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000355534A (ja) * 1999-03-24 2000-12-26 Rheox Inc 薬剤、塗料ボールおよび他の調合物に使用することのできる、ゼラチンを含まない可撓性のあるカプセル材
JP2001170137A (ja) * 1999-12-16 2001-06-26 Shionogi Qualicaps Kk 硬質カプセル及びその製造方法
JP2002212063A (ja) * 2000-11-17 2002-07-31 Takeda Chem Ind Ltd コポリビドン含有製剤
JP2004250369A (ja) * 2003-02-19 2004-09-09 Fuji Capsule Kk 軟カプセル剤皮膜組成物

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008237572A (ja) * 2007-03-27 2008-10-09 Sankyo:Kk 非動物由来のソフトカプセル外皮並びにこれを有したソフトカプセル
WO2008117682A1 (fr) * 2007-03-27 2008-10-02 Sankyo Co., Ltd. Enveloppe de capsule molle, ne provenant pas d'un animal, et capsule molle pourvue de celle-ci
JP4875769B2 (ja) * 2008-09-26 2012-02-15 株式会社三協 ソフトカプセルの製造方法並びにその製造装置
US8572933B2 (en) 2008-09-26 2013-11-05 Sankyo Co., Ltd. Method for manufacturing soft capsule and apparatus for manufacturing the same
JP2017039724A (ja) * 2009-06-19 2017-02-23 富士カプセル株式会社 ソフトカプセル及びその製造方法
JP2012001553A (ja) * 2009-06-19 2012-01-05 Fuji Capsule Kk ソフトカプセル及びその製造方法
JP4822299B2 (ja) * 2009-06-19 2011-11-24 富士カプセル株式会社 ソフトカプセル及びその製造方法
JP2011057746A (ja) * 2009-09-07 2011-03-24 Dai Ichi Kogyo Seiyaku Co Ltd ゲル状組成物
JP2013537902A (ja) * 2011-04-20 2013-10-07 サフン カプセル カンパニー， リミテッド 崩解度及び被膜硬度を改善した非動物性軟質カプセル被膜組成物
CN106243408A (zh) * 2016-08-26 2016-12-21 湖南尔康制药股份有限公司 一种改善机械性能的淀粉胶囊
WO2018225770A1 (fr) * 2017-06-09 2018-12-13 富士カプセル株式会社 Composition pour film de capsule sans soudure, et capsule sans soudure
JPWO2018225770A1 (ja) * 2017-06-09 2020-04-09 富士カプセル株式会社 シームレスカプセル皮膜用組成物及びシームレスカプセル
US11364206B2 (en) 2017-06-09 2022-06-21 Fuji Capsule Co., Ltd. Seamless capsule shell composition and seamless capsule
JP7174383B2 (ja) 2017-06-09 2022-11-17 富士カプセル株式会社 シームレスカプセル皮膜用組成物及びシームレスカプセル
CN109364039A (zh) * 2018-09-21 2019-02-22 浙江中同科技有限公司 一种淀粉空心胶囊及其制备方法

Similar Documents

Publication Publication Date Title
JP5248739B2 (ja) 腸溶性調製物
CA2870134A1 (fr) Dispersions aqueuses d'acetate et succinate d'hydroxypropylmethylcellulose (hpmcas)
WO2005105051A1 (fr) Gelules ameliorees de pullulan
TW200409655A (en) Non-gelatin type encapsulating composition and capsule obtained therefrom
JP2004507581A (ja) ペクチンフィルム組成物
EP2415485A1 (fr) Capsule dure
JP2023536022A (ja) ソフトカプセルのカプセルシェルおよびソフトカプセル
EP2111837B1 (fr) Bande de soudage pour capsules dures contenant du peg encapsulé
AU2015369696B2 (en) Enteric film coating compositions, method of coating, and coated forms
WO2006121098A1 (fr) Composition de film de capsules molles
CN114667084A (zh) 非动物性软凝胶胶囊制剂、其制备方法及使用方法
JP5289429B2 (ja) 硬質カプセル剤
JP5788256B2 (ja) シームレスカプセル充填用組成物
WO2004096283A1 (fr) Film pour capsule molle et capsule molle
CN102292110A (zh) 硬胶囊
JP5328768B2 (ja) 硬質カプセル剤
JP5705206B2 (ja) 硬カプセルおよびその製造方法
EP3363861A2 (fr) Composition polymère
EP2219621B1 (fr) Complexes trimoléculaires et leur utilisation dans des systèmes d'administration de médicaments
JP2025508474A (ja) ソフトジェルカプセル調製物
JP2023041452A (ja) 軟カプセル剤及びその製造方法、並びに軟カプセル剤の吸湿を抑制する方法
CN108159014A (zh) 一种肠溶植物胶囊

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06746257

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP